ArticleBMC urology2016
Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection.
Article in BMC urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Testosterone-Sparing Treatment Strategies for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.Current oncology reports · 2026Review
- Kurt-Semm-Center of minimally invasive and robot-assisted surgery: Over 10 years of an interdisciplinary and interprofessional project in clinical application, research and training.Journal of robotic surgery · 2026Review
- Oncologic outcomes of salvage radiotherapy and lymphadenectomy for positron emission tomography-positive lymph nodes in biochemical recurrence: A systematic review to inform treatment decisions.Prostate international · 2025Review
- Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.Prostate cancer and prostatic diseases · 2024Review
- Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy.Prostate international · 2024Article
- Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?World journal of urology · 2021Article
- Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?Current urology reports · 2020Review
- Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.European urology · 2020Article
- Article
- Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.Current oncology reports · 2019Review
- Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.European urology · 2019Article
- Surgical site infections after radical prostatectomy: A comparative study between robot-assisted laparoscopic radical prostatectomy and retropubic radical prostatectomy.Turkish journal of urology · 2018Article
- Pre-treatmentEuropean journal of hybrid imaging · 2018Article
- [Surgery for metastatic prostate cancer].Der Urologe. Ausg. A · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim was to evaluate cancer-specific survival (CSS) and overall survival (OS) in patients with prostate cancer (PCa) recurrence who underwent salvage extended pelvic lymph node dissection (ePLND), taking into consideration pre- and postoperative androgen deprivation therapy (ADT).
methodsSalvage ePLND was performed in a cohort of 54 patients with PCa recurrence, and data from 45 patients were analyzed. The indications for salvage ePLND were biochemical recurrence (BCR) of PCa and suspect findings on (11)C-choline PET/CT. PSA-level, biochemical response (BR), duration of biochemical recurrence freedom (BCRF), number of metastases, OS and CSS were analyzed retrospectively.
resultsThe average follow-up was 42.7 ± 20.8 months. Thirty-three patients (73.3 %, 95 % CI: 60.5-83.6 %) achieved BCRF during follow-up. The mean BCRF-period was 31.4 ± 19.7 months. CSS and OS were both 91.7 % ± 4.8 % (3-year survival) and 80.6 ± 8.6 % (5-year survival). Twenty-four patients (53.3 %, 95 % CI: 40.0-66.3 %) with castration-resistant PCa (CRPC) responded again to ADT after salvage ePLND.
conclusionsSalvage ePLND for selected patients with BCR and clinically recurrent nodal disease can achieve an immediate complete PSA response (i. e. BCRF) in nearly half of the patients. Patients with CRPC responded again to ADT after ePLND. Multicenter prospective studies with a control group are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.